Tocqueville Asset Management L.P. Buys New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tocqueville Asset Management L.P. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, Holdings Channel.com reports. The firm purchased 5,300 shares of the medical equipment provider’s stock, valued at approximately $560,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Atria Investments Inc grew its holdings in shares of Zimmer Biomet by 60.2% in the third quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider’s stock worth $586,000 after purchasing an additional 2,041 shares during the last quarter. Empowered Funds LLC lifted its position in Zimmer Biomet by 6.8% during the third quarter. Empowered Funds LLC now owns 4,135 shares of the medical equipment provider’s stock valued at $446,000 after buying an additional 265 shares during the period. Natixis Advisors LLC lifted its position in Zimmer Biomet by 24.7% during the third quarter. Natixis Advisors LLC now owns 63,651 shares of the medical equipment provider’s stock valued at $6,871,000 after buying an additional 12,602 shares during the period. Swiss National Bank lifted its position in Zimmer Biomet by 0.6% during the third quarter. Swiss National Bank now owns 610,700 shares of the medical equipment provider’s stock valued at $65,925,000 after buying an additional 3,500 shares during the period. Finally, Pathstone Holdings LLC lifted its position in Zimmer Biomet by 5.2% during the third quarter. Pathstone Holdings LLC now owns 73,039 shares of the medical equipment provider’s stock valued at $7,885,000 after buying an additional 3,612 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZBH has been the subject of several recent analyst reports. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Trading Up 0.0 %

Zimmer Biomet stock opened at $112.91 on Thursday. The business has a 50-day simple moving average of $106.41 and a two-hundred day simple moving average of $106.93. The company has a market cap of $22.48 billion, a P/E ratio of 25.37, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.95% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.